Home / Business and Economy / EloraTZP Data: Lilly's Next Big Bet?
EloraTZP Data: Lilly's Next Big Bet?
19 Sep
Summary
- Mid-stage data for eloraTZP, a combination drug, presented September 30.
- Stock valuation already prices in success for Lilly's obesity franchise.
- Key trial metrics include weight loss, tolerability, and discontinuation rates.
Eli Lilly (NYSE:LLY) presented mid-stage trial data for eloraTZP, a combination therapy of eloralintide and tirzepatide, at a European Association for the Study of Diabetes symposium on September 30. Earlier Phase 1 studies suggested this combination could enhance weight loss outcomes beyond tirzepatide alone. The current stock price, trading near $1,152.44, already reflects significant investor optimism regarding Lilly's obesity franchise, leaving little room for error.
Key metrics to assess eloraTZP's performance include the magnitude of weight loss achieved, the effectiveness across different dose arms, patient tolerability, and discontinuation rates. For the strategic rationale to hold, the combination must demonstrate superiority over each individual component, not just a placebo. Tolerability is crucial, as it directly impacts patient persistence and, consequently, revenue generation.
The company's existing obesity treatments, Mounjaro and Zepbound, generated $14.87 billion in the second quarter, with Mounjaro sales increasing by 91% year over year. This performance has outpaced competitors like Novo Nordisk (NYSE:NVO). Viking Therapeutics (NASDAQ:VKTX) is also a competitor with its drug VK2735. A strong showing from eloraTZP would elevate the competitive bar for these rivals.
Lilly's stock currently trades at a forward earnings multiple of 24x, against a trailing multiple of 38x, with a market capitalization around $1.01 trillion. The options market indicates caution, with put/call ratios at 2.33 for the October 2 expiration and 4.67 for October 9. The bull case for LLY stock hinges on eloraTZP showing significantly deeper weight loss and clean tolerability, supporting the franchise as retatrutide progresses toward a Q1 2027 BLA submission. CEO David A. Ricks has raised full-year revenue guidance to $85.0 billion to $87.0 billion. However, the bear case suggests that match-level efficacy with worse tolerability or higher discontinuations would render the combo redundant, potentially pressuring the company's demanding valuation.
